Cambridge, Mass. – September 25, 2026 -- NeuroSense Therapeutics (NASDAQ: NRSN) cut operating expenses to $3.4 million in the first half of 2026, down from $4.7 million a year earlier, as the biotech pushes its ALS candidate PrimeC toward a Canadian regulatory filing targeted for December 2026.
NeuroSense trims R&D and G&A spending by double digits in H1 2026
Research and development expenses fell 16% to $2,102 thousand from $2,503 thousand, driven by lower subcontractor and consultant costs, partly offset by higher share-based payment expense. General and administrative expenses dropped 38.6% to $1,345 thousand from $2,189 thousand on reduced professional services spending.
Company targets December NDS filing in Canada after Health Canada alignment
NeuroSense completed the Pre-New Drug Submission process with Health Canada, which indicated no concerns with the proposed timeline and aligned on the content and structure of the ALS submission for PrimeC. The company is preparing the NDS package, supported by expanded PARADIGM clinical, survival and biomarker data.
PARADIGM data show 65% reduction in death risk for continuously treated patients
Long-term follow-up from the Phase 2b PARADIGM study, reported in February 2026, showed a statistically significant 65% reduction in risk of death and an estimated median survival of 36.3 months for participants on continuous PrimeC treatment, versus 21.4 months for those initially on placebo before crossover. The results were published in JAMA Neurology in March 2026. In June 2026, the company said PARADIGM met its primary endpoint, showing a statistically significant reduction in extracellular vesicle-associated TDP-43, a pathology present in more than 97% of ALS cases.
NeuroSense weighs accelerated approval pathway and smaller pivotal trial design in the U.S.
The company is evaluating an AI-enabled characterization of PrimeC's formulation, a planned active-comparator study against edaravone, and a smaller, shorter pivotal PARAGON trial design. NeuroSense plans to discuss with the FDA whether existing data could support full approval or an Accelerated Approval pathway, though any revised design remains subject to FDA agreement.
Patent protection for PrimeC extended in four additional countries
During 2026, NeuroSense secured composition patent grants through 2042 in Australia, Brazil, Japan and South Korea, adding to a U.S. patent covering PrimeC use in Alzheimer's disease through 2043. The company also added Prof. Steven E. Arnold to its Scientific Advisory Board and reported positive biomarker findings from its Phase 2 RoAD proof-of-concept study in neurodegenerative disease.
Alon Ben-Noon, Chief Executive Officer of NeuroSense, said the company's priorities include advancing the Canadian regulatory pathway, preparing for the next clinical stage of PrimeC in ALS, and pursuing funding, partnerships and strategic alternatives to support continued development.